It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, ...
Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...
Longer-acting formulas have made the treatment of schizophrenia more convenient and reliable for patients. Now, stepping to the plate with another long-acting treatment are Otsuka and Lundbeck. On ...
The FINANCIAL — Teva Pharmaceutical Industries Ltd., on April 28 announced the launch of the generic equivalent to Abilify (aripiprazole) Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, in the ...
TOKYO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) ...
Abilify Asimtufii, the bipolar I disorder treatment from Otsuka and Lundbeck, has entered the world of CGI animation as part of a multichannel direct-to-consumer (DTC) campaign. The two drugmakers ...
Co confirmed that it has initiated a challenge of the patent listed by Otsuka Pharmaceutical Co., Ltd in connection with its Abilify (aripiprazole) tablets, 2mg, 5mg, 10mg, 15mg, 20mg & 30mg.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback